Metastatic prostate cancer is advanced prostate adenocarcinoma that has spread beyond the prostate and regional lymph nodes, most commonly to bone, lymph node, liver, and lung. The metastatic state is sustained by persistent androgen receptor signaling, lineage plasticity under treatment pressure, osteoblastic bone tropism, and progressive emergence of castration resistance.
Ask a research question about Metastatic Prostate Cancer. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Metastatic Prostate Cancer
creation_date: '2026-03-28T21:25:00Z'
updated_date: '2026-05-10T11:45:06Z'
description: >-
Metastatic prostate cancer is advanced prostate adenocarcinoma that has spread
beyond the prostate and regional lymph nodes, most commonly to bone, lymph node,
liver, and lung. The metastatic state is sustained by persistent androgen receptor
signaling, lineage plasticity under treatment pressure, osteoblastic bone tropism,
and progressive emergence of castration resistance.
categories:
- Genitourinary Cancer
- Metastatic Cancer
- Solid Tumor
parents:
- prostate cancer
disease_term:
preferred_term: metastatic prostate cancer
term:
id: MONDO:0008315
label: prostate cancer
mappings:
mondo_mappings:
- term:
id: MONDO:0008315
label: prostate cancer
mapping_predicate: skos:closeMatch
mapping_source: MONDO
mapping_justification: Closest MONDO parent term available for metastatic prostate cancer.
prevalence:
- population: Newly diagnosed prostate cancer
percentage: 10
notes: Approximately 10% of patients present with distant metastatic disease.
evidence:
- reference: PMID:40063046
reference_title: "Prostate Cancer: A Review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: An additional 10% of men have distant metastases that are associated with a 5-year survival rate of 37%.
explanation: This provides both metastatic-at-presentation and survival data for prostate cancer.
- population: Metastatic prostate cancer
percentage: 37
notes: Reported 5-year survival rate for metastatic prostate cancer in the JAMA review cohort summary.
evidence:
- reference: PMID:40063046
reference_title: "Prostate Cancer: A Review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Approximately 10% of patients present with metastatic prostate cancer, which has a 5-year survival rate of 37%.
explanation: This directly supports the long-term survival estimate for metastatic prostate cancer.
pathophysiology:
- name: Persistent Androgen Receptor Signaling
description: >-
Androgen receptor (AR) signaling remains the central growth and survival axis
in
metastatic prostate cancer, even after systemic androgen deprivation. Persistent
AR activity supports metastatic outgrowth and is the core therapeutic dependency
in both hormone-sensitive and castration-resistant disease.
evidence:
- reference: PMID:30535926
reference_title: "Enzalutamide: A Review in Castration-Resistant Prostate Cancer."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Oral enzalutamide (Xtandi®), a second generation androgen receptor inhibitor, is indicated for the treatment of castration-resistant prostate cancer (CRPC) in numerous countries worldwide, with specific indications in this patient population varying between individual countries.
explanation: This supports the continued importance of AR signaling in metastatic castration-resistant disease.
biological_processes:
- preferred_term: androgen receptor signaling pathway
modifier: INCREASED
term:
id: GO:0030521
label: androgen receptor signaling pathway
- name: Epithelial-Mesenchymal Transition
description: >-
Prostate cancer cells acquire mesenchymal and invasive transcriptional programs
that
reduce epithelial adhesion and increase migratory capacity, enabling escape from
the
primary tumor.
biological_processes:
- preferred_term: epithelial to mesenchymal transition
modifier: INCREASED
term:
id: GO:0001837
label: epithelial to mesenchymal transition
downstream:
- target: Metastatic Dissemination
description: EMT promotes tumor cell migration and spread to distant niches
- name: Metastatic Dissemination
description: >-
Invasive prostate cancer cells migrate through lymphatic, hematogenous, and bone-seeking
routes to establish metastatic deposits at distant sites.
biological_processes:
- preferred_term: positive regulation of cell migration
modifier: INCREASED
term:
id: GO:0030335
label: positive regulation of cell migration
- name: Osteoblastic Bone Tropism
description: >-
Bone is the dominant metastatic niche in prostate cancer. Tumor-stromal signaling
stimulates abnormal woven bone formation and couples osteoblastic and osteolytic
remodeling, producing fragile but radiographically dense skeletal lesions.
evidence:
- reference: PMID:18639279
reference_title: "Histopathological assessment of prostate cancer bone osteoblastic metastases."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: In contrast with metastases caused by other carcinomas such as breast, thyroid, kidney, and lung that destroy bone and are termed “osteolytic,” prostate cancer generally causes a bone-forming or “osteoblastic” response.
explanation: This directly supports the osteoblastic bone tropism that distinguishes metastatic prostate cancer.
biological_processes:
- preferred_term: positive regulation of ossification
modifier: INCREASED
term:
id: GO:0045778
label: positive regulation of ossification
- name: Castration Resistance
description: >-
Metastatic prostate cancer adapts to androgen deprivation through AR amplification,
AR splice variants, and bypass signaling pathways that preserve tumor growth despite
castrate testosterone levels.
biological_processes:
- preferred_term: androgen receptor signaling pathway
modifier: ABNORMAL
term:
id: GO:0030521
label: androgen receptor signaling pathway
downstream:
- target: Clonal Evolution and Lineage Plasticity
description: Treatment pressure selects resistant subclones and alternative cell states
- name: Clonal Evolution and Lineage Plasticity
description: >-
Under treatment pressure, metastatic prostate cancer accumulates resistant subclones
and can adopt alternative lineage states that support persistence after AR-targeted
therapy.
biological_processes:
- preferred_term: cell fate commitment
modifier: ABNORMAL
term:
id: GO:0045165
label: cell fate commitment
- name: Immune Evasion in Metastatic Sites
description: >-
Metastatic prostate cancer is often immunologically cold, with suppressive myeloid
programs and limited endogenous T-cell infiltration compared with more immune-responsive
solid tumors.
biological_processes:
- preferred_term: negative regulation of immune response
modifier: INCREASED
term:
id: GO:0050777
label: negative regulation of immune response
phenotypes:
- category: Musculoskeletal
name: Bone pain
frequency: VERY_FREQUENT
description: Bone metastases commonly produce diffuse or focal skeletal pain.
phenotype_term:
preferred_term: Bone pain
term:
id: HP:0002653
label: Bone pain
- category: Musculoskeletal
name: Back pain
frequency: FREQUENT
description: Vertebral metastases may present with back pain and impending cord compression.
phenotype_term:
preferred_term: Back pain
term:
id: HP:0003418
label: Back pain
- category: Musculoskeletal
name: Recurrent fractures
frequency: OCCASIONAL
description: Pathologic fractures reflect fragile metastatic bone despite its osteoblastic appearance.
phenotype_term:
preferred_term: Recurrent fractures
term:
id: HP:0002757
label: Recurrent fractures
- category: Constitutional
name: Fatigue
frequency: VERY_FREQUENT
description: Fatigue is common from advanced disease burden and long-term androgen suppression.
phenotype_term:
preferred_term: Fatigue
term:
id: HP:0012378
label: Fatigue
biochemical:
- name: Plasma testosterone
context: >-
Pharmacodynamic marker of androgen deprivation in advanced prostate cancer;
suppression toward castrate levels indicates reduced androgen ligand drive.
readouts:
- target: Persistent Androgen Receptor Signaling
relationship: PHARMACODYNAMIC_MARKER_OF
direction: POSITIVE
endpoint_context: PHARMACODYNAMIC
regulatory_endpoint_refs:
- FDA-SE-adult-cancer-015
interpretation: >-
Higher plasma testosterone indicates greater androgen ligand availability
for AR signaling, whereas effective GnRH-antagonist therapy suppresses
testosterone as the pharmacodynamic endpoint.
evidence:
- reference: PMID:40063046
reference_title: "Prostate Cancer: A Review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Treatment of metastatic prostate cancer primarily relies on androgen deprivation therapy, most commonly through medical castration with gonadotropin-releasing hormone agonists.
explanation: >-
This review supports testosterone suppression through medical castration
as a central pharmacodynamic mechanism in metastatic prostate cancer.
- reference: PMID:34771580
reference_title: "Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Understanding of the molecular mechanisms of prostate cancer has led to development of therapeutic strategies targeting androgen receptor (AR).
explanation: >-
This review supports the linked AR-signaling pathograph node that plasma
testosterone pharmacodynamically reports on.
treatments:
- name: Androgen Deprivation plus AR Pathway Inhibition
description: >-
Combination systemic therapy pairs androgen deprivation therapy with an
androgen receptor pathway inhibitor for metastatic hormone-sensitive
prostate cancer, replacing ADT monotherapy for many fit patients.
evidence:
- reference: DOI:10.1200/op-24-00690
reference_title: Real-World Evidence of Combination Therapy Use in Metastatic Hormone-Sensitive Prostate Cancer in the United States From 2017 to 2023
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has evolved with robust clinical trial evidence on the benefits of combining androgen-deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPIs; abiraterone, apalutamide, darolutamide, and enzalutamide) and/or docetaxel (DOC).
explanation: This supports ADT intensification with androgen receptor pathway inhibitors as a core systemic treatment pattern in mHSPC.
treatment_term:
preferred_term: hormone modifying therapy
term:
id: MAXO:0000283
label: hormone modifying therapy
therapeutic_agent:
- preferred_term: abiraterone
term:
id: CHEBI:68642
label: abiraterone
- preferred_term: enzalutamide
term:
id: CHEBI:68534
label: enzalutamide
target_mechanisms:
- target: Persistent Androgen Receptor Signaling
treatment_effect: INHIBITS
description: ADT and AR pathway inhibitors suppress the androgen receptor axis that remains a central growth dependency in metastatic prostate cancer.
- name: Talazoparib plus Enzalutamide
description: >-
PARP inhibitor and androgen receptor inhibitor combination therapy for
homologous recombination repair gene-mutated metastatic
castration-resistant prostate cancer.
evidence:
- reference: DOI:10.1200/jco.23.02182
reference_title: "US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: The US Food and Drug Administration (FDA) approved talazoparib with enzalutamide for first-line treatment of patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
explanation: FDA approval summary supports talazoparib plus enzalutamide for HRR-mutated first-line mCRPC.
treatment_term:
preferred_term: targeted therapy
term:
id: NCIT:C93352
label: Targeted Therapy
therapeutic_agent:
- preferred_term: talazoparib
term:
id: CHEBI:231344
label: talazoparib
- preferred_term: enzalutamide
term:
id: CHEBI:68534
label: enzalutamide
target_mechanisms:
- target: Persistent Androgen Receptor Signaling
treatment_effect: INHIBITS
description: Enzalutamide inhibits AR signaling while talazoparib targets DNA-repair vulnerability in HRR-mutated tumors.
- name: Pembrolizumab for MSI-H or dMMR Disease
description: >-
Anti-PD-1 checkpoint blockade is a biomarker-selected option for metastatic
prostate cancers with MSI-H/dMMR biology, where responses are enriched
relative to TMB-high microsatellite-stable tumors.
evidence:
- reference: DOI:10.1158/1078-0432.ccr-23-3403
reference_title: Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Patients with microsatellite instability–high/mismatch repair-deficient (MSI-H/dMMR) and high tumor mutational burden (TMB-H) prostate cancers are candidates for pembrolizumab.
explanation: This supports biomarker-selected pembrolizumab use in immunotherapy-responsive metastatic prostate cancer subsets.
treatment_term:
preferred_term: immunotherapy
term:
id: NCIT:C15262
label: Immunotherapy
therapeutic_agent:
- preferred_term: pembrolizumab
term:
id: NCIT:C106432
label: Pembrolizumab
target_mechanisms:
- target: Immune Evasion in Metastatic Sites
treatment_effect: INHIBITS
description: PD-1 blockade counteracts checkpoint-mediated immune evasion in biomarker-selected tumors with high neoantigen or mismatch-repair burden.
genetic:
- name: AR
association: Amplification or splice variant activation
notes: AR amplification and splice variants drive castration resistance.
- name: PTEN
association: Somatic loss of function
notes: PTEN loss activates PI3K-AKT signaling and is associated with aggressive metastatic disease.
- name: TP53
association: Somatic loss of function
notes: TP53 loss contributes to lineage plasticity and treatment resistance.
- name: RB1
association: Somatic loss of function
notes: RB1 loss cooperates with TP53 loss in aggressive, dedifferentiated metastatic states.
environmental:
- name: Older age
notes: Older age is a major risk factor and contributes to metastatic presentation risk.
notes: >-
Bone metastasis is the defining metastatic phenotype in prostate cancer, but liver
and lung
involvement become more common in late castration-resistant disease. The central
biologic
transition is continued AR dependence followed by adaptive AR-independent escape.
references:
- reference: DOI:10.1007/s11864-024-01215-2
title: 'Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management'
found_in:
- Metastatic_Prostate_Cancer-deep-research-falcon.md
findings:
- statement: 'Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management'
supporting_text: Opinion statementThe management of metastatic castrate-resistant prostate cancer (mCRPC) has evolved in the past decade due to substantial advances in understanding the genomic landscape and biology underpinning this form of prostate cancer.
evidence:
- reference: DOI:10.1007/s11864-024-01215-2
reference_title: 'Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management'
supports: SUPPORT
evidence_source: OTHER
snippet: Opinion statementThe management of metastatic castrate-resistant prostate cancer (mCRPC) has evolved in the past decade due to substantial advances in understanding the genomic landscape and biology underpinning this form of prostate cancer.
explanation: Deep research cited this publication as relevant literature for Metastatic Prostate Cancer.
- reference: DOI:10.1016/j.eururo.2024.04.010
title: 'EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer'
found_in:
- Metastatic_Prostate_Cancer-deep-research-falcon.md
findings:
- statement: 'EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer'
supporting_text: 'EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer'
- reference: DOI:10.1038/s41591-023-02704-x
title: 'First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial'
found_in:
- Metastatic_Prostate_Cancer-deep-research-falcon.md
findings:
- statement: Preclinical evidence has suggested an interplay between the androgen receptor, which largely drives the growth of prostate cancer cells, and poly(ADP-ribose) polymerase.
supporting_text: Preclinical evidence has suggested an interplay between the androgen receptor, which largely drives the growth of prostate cancer cells, and poly(ADP-ribose) polymerase.
evidence:
- reference: DOI:10.1038/s41591-023-02704-x
reference_title: 'First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Preclinical evidence has suggested an interplay between the androgen receptor, which largely drives the growth of prostate cancer cells, and poly(ADP-ribose) polymerase.
explanation: Deep research cited this publication as relevant literature for Metastatic Prostate Cancer.
- reference: DOI:10.1101/2025.04.15.25325837
title: 'Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic review'
found_in:
- Metastatic_Prostate_Cancer-deep-research-falcon.md
findings:
- statement: Optimal treatment selection for metastatic castration resistant prostate cancer (mCRPC) remains challenging due to evolving standards of care in castration sensitive setting.
supporting_text: Optimal treatment selection for metastatic castration resistant prostate cancer (mCRPC) remains challenging due to evolving standards of care in castration sensitive setting.
evidence:
- reference: DOI:10.1101/2025.04.15.25325837
reference_title: 'Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic review'
supports: SUPPORT
evidence_source: OTHER
snippet: Optimal treatment selection for metastatic castration resistant prostate cancer (mCRPC) remains challenging due to evolving standards of care in castration sensitive setting.
explanation: Deep research cited this publication as relevant literature for Metastatic Prostate Cancer.
- reference: DOI:10.1158/1078-0432.ccr-23-3403
title: Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
found_in:
- Metastatic_Prostate_Cancer-deep-research-falcon.md
findings:
- statement: Patients with microsatellite instability–high/mismatch repair-deficient (MSI-H/dMMR) and high tumor mutational burden (TMB-H) prostate cancers are candidates for pembrolizumab.
supporting_text: Patients with microsatellite instability–high/mismatch repair-deficient (MSI-H/dMMR) and high tumor mutational burden (TMB-H) prostate cancers are candidates for pembrolizumab.
evidence:
- reference: DOI:10.1158/1078-0432.ccr-23-3403
reference_title: Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Patients with microsatellite instability–high/mismatch repair-deficient (MSI-H/dMMR) and high tumor mutational burden (TMB-H) prostate cancers are candidates for pembrolizumab.
explanation: Deep research cited this publication as relevant literature for Metastatic Prostate Cancer.
- reference: DOI:10.1200/jco.23.02182
title: 'US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer'
found_in:
- Metastatic_Prostate_Cancer-deep-research-falcon.md
findings:
- statement: The US Food and Drug Administration (FDA) approved talazoparib with enzalutamide for first-line treatment of patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
supporting_text: The US Food and Drug Administration (FDA) approved talazoparib with enzalutamide for first-line treatment of patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
evidence:
- reference: DOI:10.1200/jco.23.02182
reference_title: 'US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: The US Food and Drug Administration (FDA) approved talazoparib with enzalutamide for first-line treatment of patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
explanation: Deep research cited this publication as relevant literature for Metastatic Prostate Cancer.
- reference: DOI:10.1200/op-24-00690
title: Real-World Evidence of Combination Therapy Use in Metastatic Hormone-Sensitive Prostate Cancer in the United States From 2017 to 2023
found_in:
- Metastatic_Prostate_Cancer-deep-research-falcon.md
findings:
- statement: Real-World Evidence of Combination Therapy Use in Metastatic Hormone-Sensitive Prostate Cancer in the United States From 2017 to 2023
supporting_text: Treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has evolved with robust clinical trial evidence on the benefits of combining androgen-deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPIs; abiraterone, apalutamide, darolutamide, and enzalutamide) and/or docetaxel (DOC).
evidence:
- reference: DOI:10.1200/op-24-00690
reference_title: Real-World Evidence of Combination Therapy Use in Metastatic Hormone-Sensitive Prostate Cancer in the United States From 2017 to 2023
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has evolved with robust clinical trial evidence on the benefits of combining androgen-deprivation therapy (ADT) with androgen receptor pathway inhibitors (ARPIs; abiraterone, apalutamide, darolutamide, and enzalutamide) and/or docetaxel (DOC).
explanation: Deep research cited this publication as relevant literature for Metastatic Prostate Cancer.
- reference: DOI:10.3322/caac.70028
title: Prostate cancer statistics, 2025
found_in:
- Metastatic_Prostate_Cancer-deep-research-falcon.md
findings:
- statement: Prostate cancer is the most common cancer among men in the United States, and the incidence of advanced disease is increasing rapidly.
supporting_text: Prostate cancer is the most common cancer among men in the United States, and the incidence of advanced disease is increasing rapidly.
evidence:
- reference: DOI:10.3322/caac.70028
reference_title: Prostate cancer statistics, 2025
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Prostate cancer is the most common cancer among men in the United States, and the incidence of advanced disease is increasing rapidly.
explanation: Deep research cited this publication as relevant literature for Metastatic Prostate Cancer.
- reference: DOI:10.3390/cancers15061849
title: Advances in PARP Inhibitors for Prostate Cancer
found_in:
- Metastatic_Prostate_Cancer-deep-research-falcon.md
findings:
- statement: Poly-adenosine diphosphate-ribose polymerase plays an essential role in cell function by regulating apoptosis, genomic stability and DNA repair.
supporting_text: Poly-adenosine diphosphate-ribose polymerase plays an essential role in cell function by regulating apoptosis, genomic stability and DNA repair.
evidence:
- reference: DOI:10.3390/cancers15061849
reference_title: Advances in PARP Inhibitors for Prostate Cancer
supports: SUPPORT
evidence_source: OTHER
snippet: Poly-adenosine diphosphate-ribose polymerase plays an essential role in cell function by regulating apoptosis, genomic stability and DNA repair.
explanation: Deep research cited this publication as relevant literature for Metastatic Prostate Cancer.
- reference: DOI:10.3390/cancers15092552
title: Management of Advanced Prostate Cancer in the Precision Oncology Era
found_in:
- Metastatic_Prostate_Cancer-deep-research-falcon.md
findings:
- statement: Prostate cancer (PC) is the second leading cause of cancer death in men in the United States.
supporting_text: Prostate cancer (PC) is the second leading cause of cancer death in men in the United States.
evidence:
- reference: DOI:10.3390/cancers15092552
reference_title: Management of Advanced Prostate Cancer in the Precision Oncology Era
supports: SUPPORT
evidence_source: OTHER
snippet: Prostate cancer (PC) is the second leading cause of cancer death in men in the United States.
explanation: Deep research cited this publication as relevant literature for Metastatic Prostate Cancer.
- reference: DOI:10.3390/ijms262311665
title: 'Therapeutic Advances in Metastatic Prostate Cancer: A Journey from Standard of Care to New Emerging Treatment'
found_in:
- Metastatic_Prostate_Cancer-deep-research-falcon.md
findings:
- statement: Prostate cancer (PCa) remains one of the most prevalent malignancies among men worldwide and continues to pose significant therapeutic challenges, especially in its metastatic and castration-resistant forms.
supporting_text: Prostate cancer (PCa) remains one of the most prevalent malignancies among men worldwide and continues to pose significant therapeutic challenges, especially in its metastatic and castration-resistant forms.
evidence:
- reference: DOI:10.3390/ijms262311665
reference_title: 'Therapeutic Advances in Metastatic Prostate Cancer: A Journey from Standard of Care to New Emerging Treatment'
supports: SUPPORT
evidence_source: OTHER
snippet: Prostate cancer (PCa) remains one of the most prevalent malignancies among men worldwide and continues to pose significant therapeutic challenges, especially in its metastatic and castration-resistant forms.
explanation: Deep research cited this publication as relevant literature for Metastatic Prostate Cancer.
Metastatic prostate cancer is prostate adenocarcinoma that has disseminated beyond the prostate and regional tissues to distant sites (AJCC M1 disease), most commonly bone and lymph nodes. Clinically, metastatic disease is often subclassified by response to androgen deprivation therapy (ADT) into: - Metastatic hormone-sensitive prostate cancer (mHSPC): metastatic disease that has not yet developed resistance to castration-level testosterone. - Metastatic castration-resistant prostate cancer (mCRPC): metastatic disease with progression despite ongoing ADT and castrate testosterone levels.
A recent review describes the mCRPC state as progression despite castrate testosterone levels (often defined as <50 ng/dL) and diagnosis by biochemical (rising PSA) and/or radiologic progression while on ADT (cicchetti2025therapeuticadvancesin pages 1-2).
The evidence used here comes from aggregated disease-level resources (EAU guideline; CA Cancer J Clin population statistics), clinical trials and regulatory summaries, and real-world claims/registry studies, rather than single-patient EHR narratives (tilki2024eaueanmestroesurisupsiogguidelineson pages 1-3, kratzer2025prostatecancerstatistics pages 1-2, raval2025realworldevidenceof pages 1-2).
EAU 2024 guideline resource URL: https://doi.org/10.1016/j.eururo.2024.04.010 (published online 2024-08) (tilki2024eaueanmestroesurisupsiogguidelineson pages 1-3).
Metastatic progression and castration resistance are strongly driven by androgen receptor (AR) biology and clonal evolution under hormonal selection pressure. A contemporary mCRPC review states: “The androgen signalling pathway plays a pivotal role in the development of castration resistance” (kulasegaran2024metastaticcastrationresistantprostate pages 3-5). Mechanisms of AR-driven resistance include alterations such as AR pathway amplification/activation and adaptation to low androgen environments (tisseverasinghe2023advancesinparp pages 2-4).
Genomically, mCRPC frequently harbors tumor suppressor and pathway alterations. One review reports “40%–60% of mCRPC cases exhibit aberrations in the AR ... tumour protein p53 and PTEN genes” and that “Approximately 20% of mCRPC patients harbour abnormalities that affect DNA repair genes” (kulasegaran2024metastaticcastrationresistantprostate pages 3-5).
In the U.S., prostate cancer incidence and mortality show strong demographic disparities that influence metastatic burden. A 2025 CA Cancer J Clin statistics report notes that Black men have double the prostate cancer mortality and 67% higher incidence compared with White men (kratzer2025prostatecancerstatistics pages 1-2).
Note: Specific lifestyle/environmental risk factors (diet, smoking, occupational exposures) were not retrieved in the present corpus and therefore are not summarized here.
Not available from retrieved sources in this run.
Metastatic prostate cancer phenotypes are driven by metastatic site(s) and systemic tumor burden. Key, commonly reported manifestations include: - Bone metastasis–related pain (symptom; QoL impact significant; often drives opioid use and palliative radiotherapy). - Skeletal-related events (SREs) such as pathological fracture, spinal cord compression, need for bone radiation/surgery. - Laboratory marker: rising PSA in many patients, though lineage plasticity can produce low-PSA aggressive variants (not fully quantified in retrieved sources).
The EAU guideline describes SRE endpoints explicitly (pathological fracture, bone radiation/surgery, spinal cord compression) in the denosumab vs zoledronic acid comparison (tilki2024eaueanmestroesurisupsiogguidelineson pages 14-15).
Because HPO IDs were not provided in retrieved sources, the following are suggested standard terms (IDs should be verified against HPO): - Bone pain; back pain - Pathologic fracture - Spinal cord compression - Elevated prostate-specific antigen - Anemia (treatment-related, e.g., PARP inhibitor myelosuppression)
The mCRPC review emphasizes that treatment goals should include symptom relief and QoL preservation, noting focus on “cancer-related symptoms such as pain” (kulasegaran2024metastaticcastrationresistantprostate pages 1-3).
Homologous recombination repair (HRR) / DNA damage repair (DDR) alterations are clinically actionable in advanced disease. A 2024 mCRPC review states that “20%–25% [of mCRPC] harbouring somatic or germline alternations in DNA repair genes involved in homologous recombination,” listing common genes “BRCA2, CHEK2, ATM and BRCA1” (kulasegaran2024metastaticcastrationresistantprostate pages 3-5).
A 2023 precision oncology review similarly highlights HRR alterations in metastatic prostate cancer, with frequently altered genes including BRCA2, ATM, CDK12, CHEK2 (gillette2023managementofadvanced pages 5-6).
Specific variant-level nomenclature (e.g., BRCA2 c.XXXXdel) and allele frequencies from gnomAD/ClinVar were not available in retrieved sources in this run.
The FDA approval summary specifies that HRRm status in TALAPRO-2 was prospectively determined with a 12-gene NGS panel: “ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, and RAD51C” (heiss2024usfoodand pages 2-4).
A large genomic/clinical study defined: - “MSI-H/dMMR prostate cancer was defined as MSIsensor score ≥10 or MSIsensor score ≥3 and <10 with a deleterious MMR alteration” - “TMB-H was defined as ≥10 mutations/megabase” (lenis2024microsatelliteinstabilitytumor pages 1-3).
Not available from retrieved sources in this run.
In a cohort of 2,257 prostate cancer patients with tumor sequencing, prevalence of immunotherapy-relevant genomic subgroups was: - MSI-H/dMMR: 63/2,257 (2.8%) - TMB-H/MSS: 33/2,257 (1.5%) (lenis2024microsatelliteinstabilitytumor pages 1-3)
Among immune checkpoint blockade–treated patients: - MSI-H/dMMR: “45% ... had a RECIST response and 65% had a PSA50 response” - TMB-H/MSS: “No ... had a RECIST response and 50% had a PSA50 response” (lenis2024microsatelliteinstabilitytumor pages 1-3).
Prostate cancer is predominantly adult/older-adult onset, with metastatic presentation either de novo or after progression from localized disease.
A real-world cohort defined de novo mHSPC operationally as first metastasis within 60 days of first prostate cancer diagnosis (raval2025realworldevidenceof pages 2-4).
The transition from mHSPC to mCRPC is clinically defined by progression while maintaining castrate testosterone and ongoing ADT; detailed staging frameworks were not extracted from retrieved sources in this run.
A 2025 CA Cancer J Clin report found that overall U.S. prostate cancer incidence trends reversed from “a decline of 6.4% per year during 2007 through 2014 to an increase of 3.0% annually during 2014 through 2021” and that “distant-stage disease has increased by 2.6% annually” in men <55, and by 6.0% (55–69) and 6.2% (≥70) (kratzer2025prostatecancerstatistics pages 1-2).
Racial disparities: Black men have “double the prostate cancer mortality, with 67% higher incidence” vs White men (kratzer2025prostatecancerstatistics pages 1-2). Distant-stage 5-year survival “ranges from 36% in Black men to 43% for AAPI men” (kratzer2025prostatecancerstatistics pages 4-4).
Germline HRR alterations occur in a minority of metastatic patients (e.g., reported germline HRR prevalence ~11.8% in one summarized dataset) (gillette2023managementofadvanced pages 6-7). Specific Mendelian inheritance patterns are not directly applicable to metastatic status (which is a disease stage), but inherited predisposition variants (e.g., BRCA2) increase risk of aggressive disease.
EAU guidance notes that trial evidence defining M1 disease used CT/MRI plus bone scintigraphy and that the impact of newer imaging such as PSMA PET/CT on outcomes has not yet been tested in randomized trials (tilki2024eaueanmestroesurisupsiogguidelineson pages 7-8).
For biochemical recurrence post-prostatectomy, the EAU guideline table recommends: “Perform PSMA PET/CT if the PSA level is >0.2 ng/ml and if the results will influence subsequent treatment decisions” (strength rating weak) (tilki2024eaueanmestroesurisupsiogguidelineson pages 4-5).
For mCRPC and advanced disease, molecular testing is used to identify actionable subgroups: - HRR mutations to guide PARP inhibitor use (heiss2024usfoodand pages 2-4, heiss2024usfoodand pages 1-2). - MSI-H/dMMR / TMB-H for pembrolizumab eligibility (lenis2024microsatelliteinstabilitytumor pages 1-3).
Distant-stage prostate cancer survival has improved over time; the CA Cancer J Clin report indicates distant-stage survival improved “from 55% in the middle 2000s to 66% in 2019–2020” (kratzer2025prostatecancerstatistics pages 4-4).
The EAU 2024 guideline recommends against ADT monotherapy as initial therapy for de novo M1 patients who are eligible for combination therapy and have sufficient life expectancy (strong) (tilki2024eaueanmestroesurisupsiogguidelineson pages 6-7). It strongly recommends ADT combined with AR pathway inhibitor options (abiraterone acetate plus prednisone, apalutamide, or enzalutamide) for fit patients (tilki2024eaueanmestroesurisupsiogguidelineson pages 7-8).
Triplet therapy evidence is incorporated: in the PEACE-1 subgroup, adding abiraterone to ADT+docetaxel improved rPFS (HR 0.50) and OS (HR 0.75) (tilki2024eaueanmestroesurisupsiogguidelineson pages 7-8).
Real-world uptake (US 2017–2023): In a claims-based cohort of 10,717 individuals, ADT+ARPI increased from 13% to 47%, and triplet therapy (ADT+ARPI+docetaxel) increased from 0.8% to 15%, while ADT alone declined from 74% to 36% (raval2025realworldevidenceof pages 1-2).
Guideline recommendation table (visual evidence): EAU 2024 Table 6 summarizes first-line mHSPC recommendations with strength ratings (tilki2024eaueanmestroesurisupsiogguidelineson media 3226c7f4).
Examples of established systemic therapies and outcomes summarized in a 2024 mCRPC review include: - Docetaxel (TAX-327): median OS 19.2 vs 16.3 months (p < 0.004) (kulasegaran2024metastaticcastrationresistantprostate pages 1-3). - Cabazitaxel (TROPIC): OS 15.1 vs 12.7 months; HR 0.7 (p ≤ 0.0001) (kulasegaran2024metastaticcastrationresistantprostate pages 1-3, kulasegaran2024metastaticcastrationresistantprostate pages 3-5). - Enzalutamide: AFFIRM OS 18.4 vs 13.6 months (HR 0.63); PREVAIL rPFS at 12 months 65% vs 14% (HR 0.19) and OS 32.4 vs 30.2 months (HR 0.7) (kulasegaran2024metastaticcastrationresistantprostate pages 3-5). - Abiraterone: COU-AA-301 OS 14.8 vs 10.9 months (HR 0.65); COU-AA-302 OS 34.7 vs 30.3 months (HR 0.81) (kulasegaran2024metastaticcastrationresistantprostate pages 3-5).
The FDA approval summary states: “The US Food and Drug Administration (FDA) approved talazoparib with enzalutamide for first-line treatment of patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).” (heiss2024usfoodand pages 1-2). Efficacy in the combined HRRm population: rPFS HR 0.45 (95% CI 0.33–0.61; P < .0001); BRCA-mutated subgroup rPFS HR 0.20 (95% CI 0.11–0.36) (heiss2024usfoodand pages 1-2).
Safety is dominated by myelosuppression: decreased hemoglobin any-grade 79%; grade ≥3 anemia 45%; and RBC transfusion in 39% (heiss2024usfoodand pages 6-8).
In a large institutional cohort, MSI-H/dMMR prevalence was 2.8% and responses to ICB were substantial: 45% RECIST response and 65% PSA50 response among treated MSI-H/dMMR patients (lenis2024microsatelliteinstabilitytumor pages 1-3).
EAU guideline evidence summary: - Zoledronic acid (4 mg): fewer SREs vs placebo (33% vs 44%; p = 0.021) (tilki2024eaueanmestroesurisupsiogguidelineson pages 14-15). - Denosumab vs zoledronic acid: longer time to first on-study SRE (20.7 vs 17.1 months; HR 0.82; p = 0.008) (tilki2024eaueanmestroesurisupsiogguidelineson pages 14-15).
Key toxicities include osteonecrosis of the jaw (reported 8.2% in mCRPC) and severe hypocalcemia (8% with denosumab vs 5% with zoledronic acid), motivating dental exam prior to therapy and calcium/vitamin D supplementation (tilki2024eaueanmestroesurisupsiogguidelineson pages 14-15).
Not addressed in retrieved sources.
Population screening and its association with stage at diagnosis is addressed indirectly via incidence trend analyses. A large multistate cohort found that higher county-level PSA screening prevalence prior to diagnosis was associated with lower odds of advanced stage and lower mortality (kratzer2025prostatecancerstatistics pages 5-6).
Note: Specific USPSTF recommendations were not retrieved in full text in this run.
Not available from retrieved sources in this run.
Not available from retrieved sources in this run.
Key 2023–2024 developments and implementation signals include: - EAU 2024 guideline updates integrating ARPI intensification and selective triplet therapy in mHSPC (tilki2024eaueanmestroesurisupsiogguidelineson pages 6-7, tilki2024eaueanmestroesurisupsiogguidelineson pages 7-8). - Biomarker-driven first-line mCRPC approval of talazoparib + enzalutamide for HRR gene–mutated disease, with strongest rPFS benefit in BRCA-mutated subgroup (heiss2024usfoodand pages 1-2). - Clarified immunotherapy biomarker performance: MSI-H/dMMR vs TMB-H/MSS distinction, with durable objective responses concentrated in MSI-H/dMMR (lenis2024microsatelliteinstabilitytumor pages 1-3). - Real-world adoption: by 2023, ADT+ARPI (47%) and ADT+ARPI+docetaxel (15%) increased substantially, though 36% still received ADT alone (raval2025realworldevidenceof pages 1-2).
| Topic/Section | Key finding (with numeric data) | Source (first author, year, journal) | Publication date | PMID | URL/DOI |
|---|---|---|---|---|---|
| Definitions/guideline framework for relapsing & metastatic disease | 2024 EAU Part II update summarizes evidence reviewed from 2020-2023; for de novo M1 disease, ADT monotherapy should not be offered if patients are suitable for combination therapy; recommends ADT + ARPI for fit patients and ADT + prostate RT for de novo low-volume disease by CHAARTED criteria; PEACE-1 subgroup cited with rPFS HR 0.50 and OS HR 0.75 for triplet therapy context (tilki2024eaueanmestroesurisupsiogguidelineson pages 1-3, tilki2024eaueanmestroesurisupsiogguidelineson pages 7-8, tilki2024eaueanmestroesurisupsiogguidelineson pages 6-7) | Tilki, 2024, European Urology | 2024-08 | http://hdl.handle.net/1874/455097 ; https://doi.org/10.1016/j.eururo.2024.04.010 | |
| Precision therapy / FDA approval | FDA approved talazoparib + enzalutamide on 2023-06-20 for adult patients with HRR gene-mutated mCRPC; TALAPRO-2 showed rPFS HR 0.45 (95% CI 0.33-0.61) in HRRm population and BRCA subgroup HR 0.20 (95% CI 0.11-0.36); grade ≥3 anemia 45%, neutropenia 18%, thrombocytopenia 8%; RBC transfusion in 39% (heiss2024usfoodand pages 6-8, heiss2024usfoodand pages 2-4, heiss2024usfoodand pages 1-2) | Heiss, 2024, Journal of Clinical Oncology | 2024-05 | https://doi.org/10.1200/jco.23.02182 | |
| Phase 3 HRR-deficient mCRPC trial | In combined HRR-deficient population (N=399), talazoparib + enzalutamide improved rPFS: median not reached vs 13.8 months; HR 0.45 (95% CI 0.33-0.61; P<0.0001); OS immature but favored combination, HR 0.69 (95% CI 0.46-1.03); common AEs were anemia, fatigue, neutropenia (fizazi2024firstlinetalazoparibwith pages 2-3, fizazi2024firstlinetalazoparibwith pages 1-2) | Fizazi, 2024, Nature Medicine | 2024-12 | https://doi.org/10.1038/s41591-023-02704-x | |
| Immunotherapy biomarkers (MSI/TMB) | Among 2,257 patients, MSI-H/dMMR prevalence was 2.8% and TMB-H/MSS 1.5%; definitions: MSI-H/dMMR = MSIsensor ≥10 or 3-10 with deleterious MMR alteration; TMB-H = ≥10 mut/Mb; with ICB, MSI-H/dMMR had 45% RECIST response and 65% PSA50 response, versus 0% RECIST and 50% PSA50 for TMB-H/MSS (lenis2024microsatelliteinstabilitytumor pages 1-3, lenis2024microsatelliteinstabilitytumor pages 3-5) | Lenis, 2024, Clinical Cancer Research | 2024-07 | https://doi.org/10.1158/1078-0432.ccr-23-3403 | |
| Epidemiology / incidence trends / disparities | US prostate cancer incidence reversed from -6.4%/year (2007-2014) to +3.0%/year (2014-2021); distant-stage disease increased annually by 2.6% (<55 y), 6.0% (55-69 y), and 6.2% (≥70 y); Black men had double prostate cancer mortality and 67% higher incidence than White men (kratzer2025prostatecancerstatistics pages 1-2, kratzer2025prostatecancerstatistics pages 3-4) | Kratzer, 2025, CA: A Cancer Journal for Clinicians | 2025-09 | https://doi.org/10.3322/caac.70028 | |
| Real-world mHSPC treatment adoption | In 10,717 US patients with mHSPC (median age 65), 62% had de novo disease; from 2017 to 2023, ADT+ARPI increased from 13% to 47%, ADT+ARPI+docetaxel from 0.8% to 15%, ADT+docetaxel declined from 12% to 3%, and ADT alone from 74% to 36% (raval2025realworldevidenceof pages 1-2, raval2025realworldevidenceof pages 2-4) | Raval, 2025, JCO Oncology Practice | 2025-02 | https://doi.org/10.1200/op-24-00690 | |
| mCRPC treatment landscape / genomics | mCRPC remains incurable but treatment sequencing is increasingly biomarker-informed; docetaxel TAX327 median OS 19.2 vs 16.3 months, cabazitaxel TROPIC OS 15.1 vs 12.7 months (HR 0.7); 20%-25% of mCRPC harbor somatic/germline DNA repair (HRR) alterations, and 40%-60% show AR/TP53/PTEN aberrations (kulasegaran2024metastaticcastrationresistantprostate pages 3-5, kulasegaran2024metastaticcastrationresistantprostate pages 1-3) | Kulasegaran, 2024, Current Treatment Options in Oncology | 2024-06 | https://doi.org/10.1007/s11864-024-01215-2 | |
| Systemic therapy evidence synthesis / sequencing | Living systematic review included 143 randomized trials and 17,523 patients; reported median mCRPC survival 25.6 months; PARPi+ARPI favored for BRCA+ first-line disease, PARPi monotherapy after prior ARPI in BRCA+ disease; for non-HRR-altered disease, active options include abiraterone, enzalutamide, cabazitaxel, docetaxel, and Lu177 if PSMA-positive (naqvi2025systemictreatmentoptions pages 1-5, naqvi2025systemictreatmentoptions pages 18-21) | Naqvi, 2025, medRxiv | 2025-04 | https://doi.org/10.1101/2025.04.15.25325837 |
Table: This table summarizes major 2024-2025 evidence sources used for metastatic prostate cancer, spanning guidelines, biomarker-driven therapy, epidemiology, and real-world implementation. It highlights key quantitative findings and links them to authoritative publications for rapid reference.
EAU 2024 Table 6 (cropped image) includes first-line mHSPC treatment recommendations with strength ratings (tilki2024eaueanmestroesurisupsiogguidelineson media 3226c7f4).
References
(cicchetti2025therapeuticadvancesin pages 1-2): Rossella Cicchetti, Martina Basconi, Giulio Litterio, Angelo Orsini, Marco Mascitti, Alessio Digiacomo, Gaetano Salzano, Octavian Sabin Tătaru, Matteo Ferro, Carlo Giulioni, Angelo Cafarelli, Luigi Schips, and Michele Marchioni. Therapeutic advances in metastatic prostate cancer: a journey from standard of care to new emerging treatment. International Journal of Molecular Sciences, 26:11665, Dec 2025. URL: https://doi.org/10.3390/ijms262311665, doi:10.3390/ijms262311665. This article has 5 citations.
(kratzer2025prostatecancerstatistics pages 2-3): Tyler B. Kratzer, Natalia Mazzitelli, Jessica Star, William L. Dahut, Ahmedin Jemal, and Rebecca L. Siegel. Prostate cancer statistics, 2025. CA: A Cancer Journal for Clinicians, 75:485-497, Sep 2025. URL: https://doi.org/10.3322/caac.70028, doi:10.3322/caac.70028. This article has 103 citations and is from a domain leading peer-reviewed journal.
(tilki2024eaueanmestroesurisupsiogguidelineson pages 1-3): D Tilki, RCN van den Bergh, and E Briers. Eau-eanm-estro-esur-isup-siog guidelines on prostate cancer. part ii—. Unknown journal, 2024.
(kratzer2025prostatecancerstatistics pages 1-2): Tyler B. Kratzer, Natalia Mazzitelli, Jessica Star, William L. Dahut, Ahmedin Jemal, and Rebecca L. Siegel. Prostate cancer statistics, 2025. CA: A Cancer Journal for Clinicians, 75:485-497, Sep 2025. URL: https://doi.org/10.3322/caac.70028, doi:10.3322/caac.70028. This article has 103 citations and is from a domain leading peer-reviewed journal.
(raval2025realworldevidenceof pages 1-2): Amit D. Raval, Orsolya Lunacsek, Matthew J. Korn, Natasha Littleton, Niculae Constantinovici, and Daniel J. George. Real-world evidence of combination therapy use in metastatic hormone-sensitive prostate cancer in the united states from 2017 to 2023. JCO Oncology Practice, 21:1174-1184, Feb 2025. URL: https://doi.org/10.1200/op-24-00690, doi:10.1200/op-24-00690. This article has 10 citations and is from a peer-reviewed journal.
(kulasegaran2024metastaticcastrationresistantprostate pages 3-5): Tivya Kulasegaran and Niara Oliveira. Metastatic castration-resistant prostate cancer: advances in treatment and symptom management. Current Treatment Options in Oncology, 25:914-931, Jun 2024. URL: https://doi.org/10.1007/s11864-024-01215-2, doi:10.1007/s11864-024-01215-2. This article has 75 citations and is from a peer-reviewed journal.
(tisseverasinghe2023advancesinparp pages 2-4): Steven Tisseverasinghe, Boris Bahoric, Maurice Anidjar, Stephan Probst, and Tamim Niazi. Advances in parp inhibitors for prostate cancer. Cancers, 15:1849, Mar 2023. URL: https://doi.org/10.3390/cancers15061849, doi:10.3390/cancers15061849. This article has 29 citations.
(tilki2024eaueanmestroesurisupsiogguidelineson pages 14-15): D Tilki, RCN van den Bergh, and E Briers. Eau-eanm-estro-esur-isup-siog guidelines on prostate cancer. part ii—. Unknown journal, 2024.
(kulasegaran2024metastaticcastrationresistantprostate pages 1-3): Tivya Kulasegaran and Niara Oliveira. Metastatic castration-resistant prostate cancer: advances in treatment and symptom management. Current Treatment Options in Oncology, 25:914-931, Jun 2024. URL: https://doi.org/10.1007/s11864-024-01215-2, doi:10.1007/s11864-024-01215-2. This article has 75 citations and is from a peer-reviewed journal.
(gillette2023managementofadvanced pages 5-6): Claire M. Gillette, Gabriel A. Yette, Scott D. Cramer, and Laura S. Graham. Management of advanced prostate cancer in the precision oncology era. Cancers, 15:2552, Apr 2023. URL: https://doi.org/10.3390/cancers15092552, doi:10.3390/cancers15092552. This article has 20 citations.
(heiss2024usfoodand pages 2-4): Brian L. Heiss, Elaine Chang, Xin Gao, Tien Truong, Michael H. Brave, Erik Bloomquist, Ankit Shah, Salaheldin Hamed, Jeffrey Kraft, Haw-Jyh Chiu, Tiffany K. Ricks, Amy Tilley, William F. Pierce, Liuya Tang, Abdelrahmman Abukhdeir, Shyam Kalavar, Reena Philip, Shenghui Tang, Richard Pazdur, Laleh Amiri-Kordestani, Paul G. Kluetz, and Daniel L. Suzman. Us food and drug administration approval summary: talazoparib in combination with enzalutamide for treatment of patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 42:1851-1860, May 2024. URL: https://doi.org/10.1200/jco.23.02182, doi:10.1200/jco.23.02182. This article has 30 citations and is from a highest quality peer-reviewed journal.
(lenis2024microsatelliteinstabilitytumor pages 1-3): Andrew T. Lenis, Vignesh Ravichandran, Samantha Brown, Syed M. Alam, Andrew Katims, Hong Truong, Peter A. Reisz, Samantha Vasselman, Barbara Nweji, Karen A. Autio, Michael J. Morris, Susan F. Slovin, Dana Rathkopf, Daniel Danila, Sungmin Woo, Hebert A. Vargas, Vincent P. Laudone, Behfar Ehdaie, Victor Reuter, Maria Arcila, Michael F. Berger, Agnes Viale, Howard I. Scher, Nikolaus Schultz, Anuradha Gopalan, Mark T.A. Donoghue, Irina Ostrovnaya, Konrad H. Stopsack, David B. Solit, and Wassim Abida. Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:3894-3903, Jul 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-3403, doi:10.1158/1078-0432.ccr-23-3403. This article has 62 citations.
(raval2025realworldevidenceof pages 2-4): Amit D. Raval, Orsolya Lunacsek, Matthew J. Korn, Natasha Littleton, Niculae Constantinovici, and Daniel J. George. Real-world evidence of combination therapy use in metastatic hormone-sensitive prostate cancer in the united states from 2017 to 2023. JCO Oncology Practice, 21:1174-1184, Feb 2025. URL: https://doi.org/10.1200/op-24-00690, doi:10.1200/op-24-00690. This article has 10 citations and is from a peer-reviewed journal.
(kratzer2025prostatecancerstatistics pages 4-4): Tyler B. Kratzer, Natalia Mazzitelli, Jessica Star, William L. Dahut, Ahmedin Jemal, and Rebecca L. Siegel. Prostate cancer statistics, 2025. CA: A Cancer Journal for Clinicians, 75:485-497, Sep 2025. URL: https://doi.org/10.3322/caac.70028, doi:10.3322/caac.70028. This article has 103 citations and is from a domain leading peer-reviewed journal.
(gillette2023managementofadvanced pages 6-7): Claire M. Gillette, Gabriel A. Yette, Scott D. Cramer, and Laura S. Graham. Management of advanced prostate cancer in the precision oncology era. Cancers, 15:2552, Apr 2023. URL: https://doi.org/10.3390/cancers15092552, doi:10.3390/cancers15092552. This article has 20 citations.
(tilki2024eaueanmestroesurisupsiogguidelineson pages 7-8): D Tilki, RCN van den Bergh, and E Briers. Eau-eanm-estro-esur-isup-siog guidelines on prostate cancer. part ii—. Unknown journal, 2024.
(tilki2024eaueanmestroesurisupsiogguidelineson pages 4-5): D Tilki, RCN van den Bergh, and E Briers. Eau-eanm-estro-esur-isup-siog guidelines on prostate cancer. part ii—. Unknown journal, 2024.
(heiss2024usfoodand pages 1-2): Brian L. Heiss, Elaine Chang, Xin Gao, Tien Truong, Michael H. Brave, Erik Bloomquist, Ankit Shah, Salaheldin Hamed, Jeffrey Kraft, Haw-Jyh Chiu, Tiffany K. Ricks, Amy Tilley, William F. Pierce, Liuya Tang, Abdelrahmman Abukhdeir, Shyam Kalavar, Reena Philip, Shenghui Tang, Richard Pazdur, Laleh Amiri-Kordestani, Paul G. Kluetz, and Daniel L. Suzman. Us food and drug administration approval summary: talazoparib in combination with enzalutamide for treatment of patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 42:1851-1860, May 2024. URL: https://doi.org/10.1200/jco.23.02182, doi:10.1200/jco.23.02182. This article has 30 citations and is from a highest quality peer-reviewed journal.
(tilki2024eaueanmestroesurisupsiogguidelineson pages 6-7): D Tilki, RCN van den Bergh, and E Briers. Eau-eanm-estro-esur-isup-siog guidelines on prostate cancer. part ii—. Unknown journal, 2024.
(tilki2024eaueanmestroesurisupsiogguidelineson media 3226c7f4): D Tilki, RCN van den Bergh, and E Briers. Eau-eanm-estro-esur-isup-siog guidelines on prostate cancer. part ii—. Unknown journal, 2024.
(heiss2024usfoodand pages 6-8): Brian L. Heiss, Elaine Chang, Xin Gao, Tien Truong, Michael H. Brave, Erik Bloomquist, Ankit Shah, Salaheldin Hamed, Jeffrey Kraft, Haw-Jyh Chiu, Tiffany K. Ricks, Amy Tilley, William F. Pierce, Liuya Tang, Abdelrahmman Abukhdeir, Shyam Kalavar, Reena Philip, Shenghui Tang, Richard Pazdur, Laleh Amiri-Kordestani, Paul G. Kluetz, and Daniel L. Suzman. Us food and drug administration approval summary: talazoparib in combination with enzalutamide for treatment of patients with homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. Journal of Clinical Oncology, 42:1851-1860, May 2024. URL: https://doi.org/10.1200/jco.23.02182, doi:10.1200/jco.23.02182. This article has 30 citations and is from a highest quality peer-reviewed journal.
(kratzer2025prostatecancerstatistics pages 5-6): Tyler B. Kratzer, Natalia Mazzitelli, Jessica Star, William L. Dahut, Ahmedin Jemal, and Rebecca L. Siegel. Prostate cancer statistics, 2025. CA: A Cancer Journal for Clinicians, 75:485-497, Sep 2025. URL: https://doi.org/10.3322/caac.70028, doi:10.3322/caac.70028. This article has 103 citations and is from a domain leading peer-reviewed journal.
(fizazi2024firstlinetalazoparibwith pages 2-3): Karim Fizazi, Arun A. Azad, Nobuaki Matsubara, Joan Carles, Andre P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C. C. Fong, Eric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Cynthia G. Healy, Nicola Di Santo, A. Douglas Laird, Fabian Zohren, and Neeraj Agarwal. First-line talazoparib with enzalutamide in hrr-deficient metastatic castration-resistant prostate cancer: the phase 3 talapro-2 trial. Nature Medicine, 30:257-264, Dec 2024. URL: https://doi.org/10.1038/s41591-023-02704-x, doi:10.1038/s41591-023-02704-x. This article has 157 citations and is from a highest quality peer-reviewed journal.
(fizazi2024firstlinetalazoparibwith pages 1-2): Karim Fizazi, Arun A. Azad, Nobuaki Matsubara, Joan Carles, Andre P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C. C. Fong, Eric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschäbitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Cynthia G. Healy, Nicola Di Santo, A. Douglas Laird, Fabian Zohren, and Neeraj Agarwal. First-line talazoparib with enzalutamide in hrr-deficient metastatic castration-resistant prostate cancer: the phase 3 talapro-2 trial. Nature Medicine, 30:257-264, Dec 2024. URL: https://doi.org/10.1038/s41591-023-02704-x, doi:10.1038/s41591-023-02704-x. This article has 157 citations and is from a highest quality peer-reviewed journal.
(lenis2024microsatelliteinstabilitytumor pages 3-5): Andrew T. Lenis, Vignesh Ravichandran, Samantha Brown, Syed M. Alam, Andrew Katims, Hong Truong, Peter A. Reisz, Samantha Vasselman, Barbara Nweji, Karen A. Autio, Michael J. Morris, Susan F. Slovin, Dana Rathkopf, Daniel Danila, Sungmin Woo, Hebert A. Vargas, Vincent P. Laudone, Behfar Ehdaie, Victor Reuter, Maria Arcila, Michael F. Berger, Agnes Viale, Howard I. Scher, Nikolaus Schultz, Anuradha Gopalan, Mark T.A. Donoghue, Irina Ostrovnaya, Konrad H. Stopsack, David B. Solit, and Wassim Abida. Microsatellite instability, tumor mutational burden, and response to immune checkpoint blockade in patients with prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 30:3894-3903, Jul 2024. URL: https://doi.org/10.1158/1078-0432.ccr-23-3403, doi:10.1158/1078-0432.ccr-23-3403. This article has 62 citations.
(kratzer2025prostatecancerstatistics pages 3-4): Tyler B. Kratzer, Natalia Mazzitelli, Jessica Star, William L. Dahut, Ahmedin Jemal, and Rebecca L. Siegel. Prostate cancer statistics, 2025. CA: A Cancer Journal for Clinicians, 75:485-497, Sep 2025. URL: https://doi.org/10.3322/caac.70028, doi:10.3322/caac.70028. This article has 103 citations and is from a domain leading peer-reviewed journal.
(naqvi2025systemictreatmentoptions pages 1-5): Syed Arsalan Ahmed Naqvi, Muhammad Umair Anjum, Arifa Bibi, Muhammad Ali Khan, Kaneez Zahra Rubab Khakwani, Huan He, Manal Imran, Syeda Zainab Kazmi, Ammad Raina, Ewan K. Cobran, R. Bryan Rumble, Thomas K. Oliver, Neeraj Agarwal, Yousef Zakharia, Mary-Ellen Taplin, Oliver Sartor, Parminder Singh, Jacob J. Orme, Daniel S. Childs, Rahul A. Parikh, Rohan Garje, Mohammad Hassan Murad, Alan H. Bryce, and Irbaz Bin Riaz. Systemic treatment options for metastatic castration resistant prostate cancer: a living systematic review. medRxiv, Apr 2025. URL: https://doi.org/10.1101/2025.04.15.25325837, doi:10.1101/2025.04.15.25325837. This article has 5 citations.
(naqvi2025systemictreatmentoptions pages 18-21): Syed Arsalan Ahmed Naqvi, Muhammad Umair Anjum, Arifa Bibi, Muhammad Ali Khan, Kaneez Zahra Rubab Khakwani, Huan He, Manal Imran, Syeda Zainab Kazmi, Ammad Raina, Ewan K. Cobran, R. Bryan Rumble, Thomas K. Oliver, Neeraj Agarwal, Yousef Zakharia, Mary-Ellen Taplin, Oliver Sartor, Parminder Singh, Jacob J. Orme, Daniel S. Childs, Rahul A. Parikh, Rohan Garje, Mohammad Hassan Murad, Alan H. Bryce, and Irbaz Bin Riaz. Systemic treatment options for metastatic castration resistant prostate cancer: a living systematic review. medRxiv, Apr 2025. URL: https://doi.org/10.1101/2025.04.15.25325837, doi:10.1101/2025.04.15.25325837. This article has 5 citations.